<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kaletsch A</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Forschungskommission der Medizinischen Fakultät der HHU</funding><funding>Dr.-Brigitte- &amp;amp;Constanze-Wegener-Stiftung</funding><pagination>100</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6069857</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investigated the novel HDACi 19i (LMK235) with presumed preferential activity against class IIA HDAC4/5 in comparison to the pan-HDACi vorinostat (SAHA) and the HDAC4-specific HDACi TMP269 in UC cell lines with basal expression of HDAC4 and characterized two HDAC4-overexpressing UC cell lines.&lt;h4>Methods&lt;/h4>Cytotoxic concentrations 50% (CC&lt;sub>50&lt;/sub>s) for HDACi were determined by MTT assay and high-content analysis-based fluorescent live/dead assay in UC cell lines with different expression o</pubmed_abstract><journal>Clinical epigenetics</journal><pubmed_title>Effects of novel HDAC inhibitors on urothelial carcinoma cells.</pubmed_title><pmcid>PMC6069857</pmcid><funding_grant_id>11</funding_grant_id><funding_grant_id>42/2015</funding_grant_id><funding_grant_id>NI 1398/1-1</funding_grant_id><pubmed_authors>Schulz WA</pubmed_authors><pubmed_authors>Hansen FK</pubmed_authors><pubmed_authors>Kassack MU</pubmed_authors><pubmed_authors>Pinkerneil M</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Kurz T</pubmed_authors><pubmed_authors>Niegisch G</pubmed_authors><pubmed_authors>Gohlke H</pubmed_authors><pubmed_authors>Kaletsch A</pubmed_authors><pubmed_authors>Hanenberg H</pubmed_authors><pubmed_authors>Hoffmann MJ</pubmed_authors><pubmed_authors>Gertzen C</pubmed_authors><pubmed_authors>Wiek C</pubmed_authors><pubmed_authors>Jaguva Vasudevan AA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of novel HDAC inhibitors on urothelial carcinoma cells.</name><description>&lt;h4>Background&lt;/h4>Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investigated the novel HDACi 19i (LMK235) with presumed preferential activity against class IIA HDAC4/5 in comparison to the pan-HDACi vorinostat (SAHA) and the HDAC4-specific HDACi TMP269 in UC cell lines with basal expression of HDAC4 and characterized two HDAC4-overexpressing UC cell lines.&lt;h4>Methods&lt;/h4>Cytotoxic concentrations 50% (CC&lt;sub>50&lt;/sub>s) for HDACi were determined by MTT assay and high-content analysis-based fluorescent live/dead assay in UC cell lines with different expression o</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jul</publication><modification>2025-04-04T20:30:53.606Z</modification><creation>2019-03-26T23:49:58Z</creation></dates><accession>S-EPMC6069857</accession><cross_references><pubmed>30064501</pubmed><doi>10.1186/s13148-018-0531-y</doi></cross_references></HashMap>